Capstone Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Capstone Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,000	Closed	-$594K	–	1605
2025 Q4	$594K	Buy	+10,000	New	+$544K	﹤0.01%	1085
2021 Q3	–	Sell	-25,000	Closed	-$2.09M	–	2007
2021 Q2	$2.09M	Sell	25,000 -42,600	-63%	-$3.38M	﹤0.01%	1009
2021 Q1	$5.1M	Sell	67,600 -2,900	-4%	-$237K	0.02%	647
2020 Q4	$6.18M	Buy	70,500 +16,000	+29%	+$1.27M	0.02%	533
2020 Q3	$4.15M	Buy	54,500 +35,000	+179%	+$3.54M	0.02%	565
2020 Q2	$2.4M	Buy	+19,500	New	+$1.94M	0.02%	651

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Capstone Investment Advisors's BMRN Position: Q2 2026 in Review

Capstone Investment Advisors opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 9,761 shares worth $559K. The stake represents ﹤0.01% of the portfolio and ranks #1186 among its holdings. This is a return to the name: Capstone Investment Advisors previously reported a position in BMRN as recently as Q1 2024.

Capstone Investment Advisors first reported a position in BMRN in Q1 2015 and has held it in 25 quarters since. The position peaked at $3.02M in Q1 2019. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Capstone Investment Advisors held 9,761 shares of BioMarin Pharmaceuticals worth $559K as of Q2 2026.
BioMarin Pharmaceuticals was a new Capstone Investment Advisors position in Q2 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q2 2026, its #1186 holding.
Capstone Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2015 and has held it in 25 quarters since.
Capstone Investment Advisors's BioMarin Pharmaceuticals position peaked at $3.02M in Q1 2019.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.